ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.245C>T (p.Pro82Leu) (rs534447939)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000161047 SCV000215716 uncertain significance Hereditary cancer-predisposing syndrome 2016-03-29 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence
Color RCV000161047 SCV000911119 benign Hereditary cancer-predisposing syndrome 2016-12-14 criteria provided, single submitter clinical testing
GeneDx RCV000213048 SCV000211777 uncertain significance not provided 2017-07-17 criteria provided, single submitter clinical testing This variant is denoted TP53 c.245C>T at the cDNA level, p.Pro82Leu (P82L) at the protein level, and results in the change of a Proline to a Leucine (CCG>CTG). This variant was shared by three of five women in a breast cancer kindred that did not demonstrate linkage to the TP53 locus and for which studied tumors did not demonstrate TP53 loss of heterozygosity (Sun 1996). While this variant has been reported to have functional transcriptional activation and normal DNA binding activity in multiple functional studies (Monti 2011, Bisio 2013, IARC TP53 database, Malcikova 2010), this residue is part of a PXXP motif in the SH3 domain, a region demonstrated to impact growth arrest in a transactivation-independent manner (Ruaro 1997). Deletion of the TP53 Pro82 residue or replacement with an Isoleucine (Pro82Ile) impacted autophosphorylation of the TP53 Ser20 residue and impaired Chk2 interaction post-irradiation (Berger 2005). Given that Leucine and Isoleucine share similar structural and chemical properties, Pro82Leu may behave in a similar manner, however assays to interrogate this have not been performed to date. TP53 Pro82Leu was not observed at a significant allele frequency in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). Since Proline and Leucine differ in some properties, this is considered a semi-conservative amino acid substitution. TP53 Pro82Leu occurs at a position that is not conserved and is located in the SH3 domain (Bode 2004). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available information, we consider TP53 Pro82Leu to be a variant of uncertain significance.
Invitae RCV000205955 SCV000259808 uncertain significance Li-Fraumeni syndrome 2018-09-30 criteria provided, single submitter clinical testing This sequence change replaces proline with leucine at codon 82 of the TP53 protein (p.Pro82Leu). The proline residue is moderately conserved and there is a moderate physicochemical difference between proline and leucine. This variant is present in population databases (rs534447939, ExAC 0.006%). This variant has been reported in a large multi-generation family with breast, cervical, bladder, and prostate cancer. Currently there is insufficient evidence to conclude whether this variant segregates with disease (PMID: 8710380). ClinVar contains an entry for this variant (Variation ID: 182946). Experimental studies have shown that this missense change does not impact TP53 binding to DNA or transactivation activity, but rather shows higher transactivational activity than the wild-type protein (PMID: 12826609, 17606709, 21343334, 20128691). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.